Health Care • Biotechnology: Pharmaceutical Preparations
$275.20 ▲ +4.16
(+1.54%)
MKT CAP: $662.49B • VOL: 6.02M
52W L $185 52W H $282
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$231
MEDIAN
$308
MEAN
$314
HIGH
$374
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE JNJ TAPE
JNJ // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $332.99 | $316.48 | 2025-02-14 | $250.43 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $346.75 | $324.74 | 2025-02-06 | $258.69 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $313.73 | $302.72 | 2025-01-29 | $264.19 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $280.70 | — | 2025-01-17 | $269.70 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $242.18 | $261.44 | 2025-01-09 | $244.93 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $327.49 | $286.21 | 2024-12-18 | $239.42 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $266.94 | $277.95 | 2024-12-04 | $255.94 | -4.3% | 48% | C |